Drug Discovery

27 Feb 2019
- Drug Discovery
- Research & Development
Imbrium, TetraGenetics announce research collaboration and license option to develop biologic therapeutics for pain

By PBR Staff Writer

Imbrium Therapeutics, a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma, and TetraGenetics, a biotech company developing novel therapeutics for pain indications and autoimmune diseases, announced a strategic research & development collaboration to utilize TetraGenetics’ antibody discovery technology platform (TetraExpress) in the discovery and development of non-opioid biologic therapies for the treatment of chronic pain.
26 Feb 2019
Drug Discovery
Research & Development
Novartis to pursue transformational therapy to reduce risk of cardiovascular disease

By PBR Staff Writer

Novartis announced that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, for targeted cardiovascular therapy.
26 Feb 2019
Drug Discovery
Research & Development
Roche to acquire gene therapy company Spark Therapeutics for $4.3bn

By PBR Staff Writer

Swiss drug maker Roche has agreed to acquire US-based gene therapy company Spark Therapeutics in an all-cash deal worth around $4.3bn.
26 Feb 2019
Drug Discovery
Research & Development
Ipsen to buy rare-disease drug maker Clementia in $1.3bn deal

By PBR Staff Writer

French pharma company Ipsen has agreed to acquire Canada-based Clementia Pharmaceuticals in an all-cash deal worth up to $1.3bn to boost its rare disease portfolio.
25 Feb 2019
Drug Discovery
Research & Development
Urovant Sciences signs $100m debt financing deal with Hercules Capital

By PBR Staff Writer

Urovant Sciences, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, announced it has entered into a debt financing agreement with Hercules Capital for up to $100m.
25 Feb 2019
Drug Discovery
Research & Development
AbbVie, Voyager sign $1.5bn gene therapy deal

By PBR Staff Writer

AbbVie and Voyager Therapeutics will engage in the development of vectorized antibodies to treat Parkinson's disease and other synucleinopathies, under a deal worth over $1.5bn.
22 Feb 2019
Drug Discovery
Research & Development
Morphic Therapeutic enters into integrin research and development collaboration with Janssen

By PBR Staff Writer

Morphic Therapeutic, a biotechnology company developing oral integrin therapies, has entered into a research and development collaboration with Janssen Biotech, to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies.
22 Feb 2019
Drug Discovery
Research & Development
Merck to buy late-stage immunotherapy firm Immune Design for $300m

By PBR Staff Writer

Merck has signed an agreement to acquire late-stage immunotherapy firm, Immune Design, in a deal valued at around $300m.
21 Feb 2019
Drug Discovery
Research & Development
Peloton Therapeutics secures $150m in Series E financing

By PBR Staff Writer

Peloton Therapeutics, a drug discovery and development company advancing oral medicines for cancer and other serious conditions, has announced the closing of an oversubscribed $150 million Series E financing.
19 Feb 2019
Drug Discovery
Research & Development
Knight Therapeutics signs Latin American funding deal with Moksha8

By PBR Staff Writer

Knight Therapeutics, a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription pharmaceutical products and Moksha8, a specialty pharmaceutical company focused on licensing and marketing innovative and established therapeutics in Latin America, announced the closing of a strategic financing agreement for up to $125m.

Drug Discovery

Research & Development

Novartis to acquire SNV4818 from Synnovation

Congruence secures $39.5m to advance small molecule correctors pipeline

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Drug Discovery

Imbrium, TetraGenetics announce research collaboration and license option to develop biologic therapeutics for pain

Novartis to pursue transformational therapy to reduce risk of cardiovascular disease

Roche to acquire gene therapy company Spark Therapeutics for $4.3bn

Ipsen to buy rare-disease drug maker Clementia in $1.3bn deal

Urovant Sciences signs $100m debt financing deal with Hercules Capital

AbbVie, Voyager sign $1.5bn gene therapy deal

Morphic Therapeutic enters into integrin research and development collaboration with Janssen

Merck to buy late-stage immunotherapy firm Immune Design for $300m

Peloton Therapeutics secures $150m in Series E financing

Knight Therapeutics signs Latin American funding deal with Moksha8

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found